CAND2

CAND2 (TIP120B) is a muscle-enriched regulator of cullin-RING ubiquitin ligase (CRL) activity that controls substrate receptor cycling and, through it, the stability of myogenic and cardiac signaling factors (PMID:17242400, PMID:40011427). It functions as an F-box protein exchange factor for CUL1-based SCF ligases, binding CUL1 with structure and affinity comparable to CAND1 but disassembling SCF less efficiently owing to a higher KM for the exchange intermediate (PMID:40011427); it acts in parallel as a bona fide CRL4 exchange factor, enhancing dynamic exchange of DDB1·DCAF substrate receptor modules with kinetics comparable to CAND1 (PMID:41864201). In muscle, CAND2 binds CUL1 and disrupts the SCF–myogenin complex, suppressing myogenin ubiquitination to stabilize this transcription factor and accelerate myogenic differentiation of C2C12 cells (PMID:17242400). CAND2 is itself a tissue-restricted substrate of the HECT E3 ligase KIAA10, which binds and ubiquitinates CAND2 (but not CAND1) specifically in muscle cells (PMID:12692129). In the heart, CAND2 is translationally upregulated downstream of mTORC1 and drives pathological cardiac remodeling by increasing GRK5 protein levels, with Cand2 deletion conferring protection (PMID:34605609). An early observation that CAND2 binds TBP and is muscle-specific established its tissue restriction (PMID:10441524); how this interaction integrates with its CRL exchange function has not been characterized in the available corpus.

1. 1999 Medium

   Established CAND2 as a distinct, muscle-specific protein and gave the first candidate interaction, linking it to the basal transcription machinery via TBP.

   Evidence GST pull-down with GST-TBP against nuclear extract, plus Northern/Western tissue profiling

   PMID:10441524

   Open questions at the time

   • No functional consequence of TBP binding shown
   • Interaction not reconciled with later CRL exchange role
   • Single-lab pull-down without reciprocal validation
2. 2003 High

   Showed CAND2 is regulated by targeted proteolysis in a tissue-restricted manner, distinguishing it from CAND1 and indicating muscle-specific control of CAND2 levels.

   Evidence Co-IP, in vitro ubiquitination, and co-transfection in C2C12 myoblasts versus Cos-1 cells with KIAA10

   PMID:12692129

   Open questions at the time

   • Physiological signal triggering CAND2 degradation unknown
   • Consequences of CAND2 turnover for CRL function not addressed
3. 2007 High

   Defined a mechanistic role for CAND2 in myogenesis by showing it protects a pro-differentiation transcription factor from SCF-mediated degradation.

   Evidence Reciprocal Co-IP, CUL1 siRNA epistasis, and myogenin ubiquitination assays in C2C12 cells

   PMID:17242400

   Open questions at the time

   • Whether stabilization reflects general exchange-factor activity or a dedicated myogenin mechanism unresolved
   • Identity of the relevant F-box receptor for myogenin not defined
4. 2021 Medium

   Extended CAND2 into cardiac pathophysiology, placing it downstream of mTORC1 as a driver of pathological growth via GRK5.

   Evidence Ribosome profiling and Cand2 knockout mouse with GRK5 protein-level readout

   PMID:34605609

   Open questions at the time

   • Molecular route from CAND2 to elevated GRK5 not defined
   • Whether CRL exchange activity mediates the GRK5 effect untested
5. 2025 High

   Provided the biochemical mechanism for CAND2 as an SCF F-box exchange factor and quantified why it is a weaker disassembler than CAND1.

   Evidence Quantitative binding, real-time kinetics, structural analysis, and cellular F-box exchange assays

   PMID:40011427

   Open questions at the time

   • Functional significance of reduced SCF exchange efficiency in vivo unclear
   • Tissue-specific consequences of the kinetic difference not addressed
6. 2026 High

   Broadened CAND2's exchange-factor function to CRL4, showing it cycles DDB1·DCAF modules with CAND1-like efficiency, unlike its weaker CRL1 activity.

   Evidence Real-time kinetics, quantitative interaction proteomics, and genetic perturbation

   PMID:41864201

   Open questions at the time

   • Specific CRL4 substrates regulated by CAND2 not enumerated
   • Why CAND2 is CRL4-efficient but CRL1-impaired structurally unresolved

• How CAND2's CRL exchange-factor activity, its TBP binding, and its tissue-specific roles in myogenesis and cardiac remodeling are mechanistically connected remains open.
• No demonstration that GRK5 or myogenin regulation requires CAND2 exchange activity
• TBP interaction unexplained in CRL context